Phase 2, Multiple-Site, Open-Label, Randomized, 2-Group, Parallel Study to Assess the Efficacy and Safety of Ryanodex(R) (EGL-4101)as Adjuvant Treatment in Subjects With Psychostimulant Drug-Induced Toxicity (PDIT)
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 03 Aug 2018
At a glance
- Drugs Dantrolene (Primary)
- Indications Drug toxicity
- Focus Therapeutic Use
- Sponsors Eagle Pharmaceuticals
- 24 Jul 2018 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 24 Jul 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 24 Jul 2018 Status changed to active, no longer recruiting.